Formulary Search
Search Results : Behavioural and Psychological Symptoms of Dementia (Olanzapine - Behavioural and Psychological Symptoms of Dementia)
Show Icon and Status Keys
- Oro-dispersible tablets
- Tablets
Initiation by a mental health specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.
- Oral solution
- Tablets
Licensed for up to 6 weeks in Alzheimer's dementia. On initiation, patients need a referal to SABP so that an assessment can be made at 6 weeks to weigh up response to treatment and benefit of treatment v risk of harm.
- Oro-dispersible tablets
Licensed for up to 6 weeks in Alzheimer's dementia. On initiation, patients need a referal to SABP so that an assessment can be made at 6 weeks to weigh up response to treatment and benefit of treatment v risk of harm.
Only for use where the liquid formulation is unsuitable e.g. for supervised administration to ensure compliance.
- Oral solution
- Tablets
Initiation by a mental health specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.
Off-label use.
- Oral solution
- Oro-dispersible tablets
- Tablets
Initiation by a mental health specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.
Initiation by a mental health specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.
- Oral solution
- Tablets
Initiation by a mental health specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.
Off-label use.
- Capsules
Initiation by a mental health specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.
Capsules are an unlicensed product.
- Immediate release tablets
Initiation by a mental health specialist and stabilisation for at least 3 months before any request to transfer prescribing responsibility.
- Modified release tablets
Modified release tablets are reserved for use when immediate release tablets are not suitable.
Modified release quetiapine MAY be continued in Primary Care (after a 3-month period of stabilisation by SABP) where the use of immediate release tablets would risk destabilising the patient.